A 2-week efficacy and safety study of eszopiclone in elderly patients with primary insomnia

Sleep

Volumn 28, Issue 6, 2005, Pages 720-727

  Scharf, Martin ^a   Erman, Milton ^b   Rosenberg, Russell ^c   Seiden, David ^d   McCall, W Vaughn ^e   Amato, David ^f   Wessel, Thomas C ^f  

^a Tri State Sleep Disorders Center   (United States)

^b Pacific Sleep Medicine Services Inc   (United States)

^c NORTHSIDE HOSPITAL   (United States)

^d Broward Research Group   (United States)

^e WAKE FOREST UNIVERSITY   (United States)

^f SUNOVION PHARMACEUTICALS INC   (United States)

Author keywords

Daytime function; Elderly; Eszopiclone; Insomnia; Quality of life; Sleep disturbance; Sleep latency; Sleep maintenance; WASO

Indexed keywords

ACETYLSALICYLIC ACID; CALCIUM; ESTROGEN; ESZOPICLONE; LEVOTHYROXINE; PARACETAMOL;

ADVERSE DRUG REACTION; AGED; ALERTNESS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; EVALUATION; FEMALE; FUNCTIONAL ASSESSMENT; HEADACHE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOMES RESEARCH; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SLEEP; SLEEP TIME; SOMNOLENCE; THORAX PAIN; UNPLEASANT TASTE; WELLBEING;

EID: 20444417371     PISSN: 01618105     EISSN: None     Source Type: Journal    
DOI: 10.1093/sleep/28.6.720     Document Type: Article

References (44)

1. Diagnostic and Statistical Manual of Mental Disorders-Text Revision, 4th ed. Washington, DC: American Psychiatric Publishing, Inc.; 2000.
2. Shochat T, Umphress J, Israel AG, Ancoli-Israel S. Insomnia in primary care patients. Sleep 1999;22(Suppl 2):S359-65.
3. Roth T, Ancoli-Israel S. Daytime consequences and correlates of insomnia in the United States: results of the 1991 National Sleep Foundation Survey. II. Sleep 1999;22(Suppl 2):S354-8.
4. Balter MB, Uhlenhuth EH. The beneficial and adverse effects of hypnotics. J Clin Psychiatry 1991;52(Suppl):16-23.
5. Janson C, Lindberg E, Gislason T, Elmasry A, Boman G. Insomnia in men - a 10-year prospective population based study. Sleep 2001;24:425-30.
6. Zammit GK, Weiner J, Damato N, Sillup GP, McMillan CA. Quality of life in people with insomnia. Sleep 1999;22(Suppl 2): S379-85.
7. Ford DE, Kamerow DB. Epidemiologic study of sleep disturbances and psychiatric disorders. An opportunity for prevention? JAMA 1989;262:1479-84.
8. Walsh JK, Engelhardt CE. The direct economic costs of insomnia in the United States for 1995. Sleep 1999;(Suppl 2):S386-93.
9. Foley DJ, Monjan AA, Brown SE, Simonsick EM, Wallace RB, Blazer DG. Sleep complaints among elderly persons: an epidemiologic study of three communities. Sleep 1995;18:425-32.
10. Ancoli-Israel S, Roth T. Characteristics of insomnia in the United States: results of the 1991 National Sleep Foundation Survey. I. Sleep 1999;(Suppl 2):S347-53.
11. Ustun TB, Privett M, Lecrubier Y, et al. Form, frequency and burden of sleep problems in general health care. Eur J Psychiatry 1996;11:5s-10.
12. Brassington GS, King AC, Bliwise DE. Sleep problems as a risk factor for falls in a sample of community-dwelling adults aged 64-99 years. J Am Geriatr Soc 2000;48:1234-40.
13. Ancoli-Israel S. Insomnia in the elderly: a review for the primary care practitioner. Sleep 2000;23(Suppl 1):S23-30.
14. McCall WV. Sleep in the elderly: burden, diagnosis, and treatment. Prim Care Companion J Clin Psychiatry 2004;6:9-20.
15. Davies M, Newell JG, Deny JM, Martin IE, Dunn SM. Characterization of the interaction of zopiclone with gamma-aminobutyric acid type A receptors. Mol Pharmacol 2000;58:756-62.
16. Krystal AD, Walsh JK, Laska E, et al. Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia. Sleep 2003;26:793-9.
17. Zammit GK, McNabb EJ, Caron J, Amato DA, Roth T. Efficacy and safety of eszopiclone across 6-weeks of treatment for primary insomnia. Curr Med Res Opin 2004;20:1979-91.
18. Monk TH, Buysse DJ, Carrier J, Billy BD, Rose ER. Effects of afternoon 'siesta' nap on sleep, alertness, performance, and circadian rhythms in the elderly. Sleep 2001;24:680-7.
19. Burssztyn M, Ginsberg G, Stessman J. The siesta and mortality in the elderly: effect of rest without sleep and daytime sleep duration. Sleep 2002;25:187-91.
20. Hays JC, Blazer DG, Foley DJ. Risk of napping: excessive daytime sleepiness and mortality in an older community population. J Am Geriatr Soc 1996;44:693-8.
21. Burazeri G, Gofin J, Kark JD. Siesta and mortality in a Mediterranean population: a community study in Jerusalem. Sleep 2003;26:578-84.
22. Bursztyn M, Ginsberg G, Hammerman-Rozenberg R, et al. The siesta in the elderly: risk factor for mortality? Arch Intern Med 1999;159:1582-6.
23. Carskadon MA, Dement WC, Mitler MM, Guilleminault C, Zarcone VP, Spiegel R. Self-reports versus sleep laboratory findings in 122 drug-free subjects with complaints of chronic insomnia. Am J Psychiatry 1976;133:1382-8.
24. Coursey RD, Frankel BL, Gaarder KR, Mott DE. A comparison of relaxation techniques with electrosleep therapy for chronic, sleep-onset insomnia: a sleep-EEG study. Biofeedback Self Regul 1980;33:615-23.
25. Frankel BL, Coursey RD, Buchbinder R, Snyder F. Recorded and reported sleep in chronic primary insomnia. Arch Gen Psychiatry 1976;33:615-23.
26. Morin CM, Kowatch RA, Barry T, Walton E. Cognitive-behavior therapy for late-life insomnia. J Consult Clin Psychology 1993;61:137-46.
27. Espie CA, Lindsay WR, Espie LC. Use of the sleep assessment device to validate insomniacs' self-report of sleep pattern. J Psychopathol Behav Assess 1989;11:71-9.
28. Lichstein KL, Johnson RS. Older adults' objective self-recording of sleep in the home. Behav Therap 1991;22:531-48.
29. Lichstein KL, Riedel B, Lester K, Aguillard N. Occult sleep apnea in a recruited sample of older adults with insomnia. J Consult Clin Psychol 1999;67:405-10.
30. Consensus Development Panel. National Institutes of Health Consensus Development Conference Statement: the treatment of sleep disorders of older people March 26-28, 1990. Sleep 1991;14:169-77.
31. Filingim JM. Double-blind evaluation of temazepam, flurazepam, and placebo in geriatric insomniacs. Clin Ther 1982;4:369-80.
32. Leppik I, Roth-Schechter GB, Gray GW, Cohn MA, Owens D. Double-blind, placebo-controlled comparison of zolpidem, triazolam, and temazepam in elderly patients with insomnia. Drug Dev Res 1997;40:230-38.
33. Hedner J, Yaeche R, Emilien G, Farr I, Salinas E. Zaleplon shortens subjective sleep latency and improves subjective sleep quality in elderly patients with insomnia. The Zaleplon Clinical Investigator Study Group. Int J Geriatr Psychiatry 2000;15:704-12.
34. Ancoli-Israel S, Walsh JK, Mangano RM, Fujimori M. Zaleplon, a novel nonbenzodiazepine hypnotic, effectively treats insomnia in elderly patients without causing rebound effects. Prim Care Companion J Clin Psychiatry 1999;1:114-20.
35. Vogel GW, Morris D. The effects of estazolam on sleep, performance, and memory: a long-term sleep laboratory study of elderly insomniacs. J Clin Pharmacol 1992;32:647-51.
36. Roehrs T, Zorick F, Wittig R, Roth T. Efficacy of a reduced triazolam dose in elderly insomniacs. Neurobiol Aging 1985;6:293-6.
37. Mamelak M, Csima A, Buck L, Price V. A comparative study on the effects of brotizolam and flurazepam on sleep and performance in the elderly. J Clin Psychopharmacol 1989;9:260-7.
38. Kummer J, Guendel L, Linden J, et al. Long-term polysomnographic study of the efficacy and safety of zolpidem in elderly psychiatric in-patients with insomnia. J Int Med Res 1993;21:171-84.
39. Shaw SH, Curson H, Coquelin JP. A double-blind, comparative study of zolpidem and placebo in the treatment of insomnia in elderly psychiatric in-patients. J Int Med Res 1992;20:150-61.
40. Roger M, Attali P, Coquelin JP. Multicenter, double-blind, controlled comparison of zolpidem and triazolam in elderly patients with insomnia. Clin Ther 1993;15:127-36.
41. Fairweather DB, Kerr JS, Hindmarch I. The effects of acute and repeated doses of zolpidem on subjective sleep, psychomotor performance and cognitive function in elderly volunteers. Eur J Clin Pharmacol 1992;43:597-601.
42. Scharf MB, Mayleben DW, Kaffeman M, Krall R, Ochs R. Dose response effects of zolpidem in normal geriatric subjects. J Clin Psychiatry 1991;52:77-83.
43. Terzano MG, Rossi M, Palomba V, Smerien A, Parrino L. New drugs for insomnia: comparative tolerability of zopiclone, zolpidem and zaleplon. Drug Saf 2003;26:261-82.
44. Beers MH. Explicit criteria for determining potentially inappropriate medication use by the elderly. An update. Arch Intern Med 1997;157:1531-6.